Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

82 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Strategies That Delay Market Entry of Generic Drugs.
Vokinger KN, Kesselheim AS, Avorn J, Sarpatwari A. Vokinger KN, et al. Among authors: sarpatwari a. JAMA Intern Med. 2017 Nov 1;177(11):1665-1669. doi: 10.1001/jamainternmed.2017.4650. JAMA Intern Med. 2017. PMID: 28975217
Using a drug-safety tool to prevent competition.
Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. N Engl J Med. 2014 Apr 17;370(16):1476-8. doi: 10.1056/NEJMp1400488. N Engl J Med. 2014. PMID: 24738666 No abstract available.
Ensuring patient privacy in data sharing for postapproval research.
Sarpatwari A, Kesselheim AS, Malin BA, Gagne JJ, Schneeweiss S. Sarpatwari A, et al. N Engl J Med. 2014 Oct 23;371(17):1644-9. doi: 10.1056/NEJMsb1405487. N Engl J Med. 2014. PMID: 25337755 No abstract available.
Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.
Sarpatwari A, Franklin JM, Avorn J, Seeger JD, Landon JE, Kesselheim AS. Sarpatwari A, et al. Clin Pharmacol Ther. 2015 Feb;97(2):186-93. doi: 10.1002/cpt.17. Epub 2014 Dec 20. Clin Pharmacol Ther. 2015. PMID: 25670524
Paying physicians to prescribe generic drugs and follow-on biologics in the United States.
Sarpatwari A, Choudhry NK, Avorn J, Kesselheim AS. Sarpatwari A, et al. PLoS Med. 2015 Mar 17;12(3):e1001802. doi: 10.1371/journal.pmed.1001802. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25781468 Free PMC article.
Progress and Hurdles for Follow-on Biologics.
Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. N Engl J Med. 2015 Jun 18;372(25):2380-2. doi: 10.1056/NEJMp1504672. Epub 2015 May 6. N Engl J Med. 2015. PMID: 25946143 No abstract available.
The 21st century cures act: Opportunities and challenges.
Sarpatwari A, Kesselheim AS. Sarpatwari A, et al. Clin Pharmacol Ther. 2015 Dec;98(6):575-7. doi: 10.1002/cpt.208. Epub 2015 Oct 8. Clin Pharmacol Ther. 2015. PMID: 26264909
Experience With the Priority Review Voucher Program for Drug Development.
Kesselheim AS, Maggs LR, Sarpatwari A. Kesselheim AS, et al. Among authors: sarpatwari a. JAMA. 2015 Oct 27;314(16):1687-8. doi: 10.1001/jama.2015.11845. JAMA. 2015. PMID: 26414802 No abstract available.
Regulatory Solutions to the Problem of High Generic Drug Costs.
Luo J, Sarpatwari A, Kesselheim AS. Luo J, et al. Among authors: sarpatwari a. Open Forum Infect Dis. 2015 Nov 13;2(4):ofv179. doi: 10.1093/ofid/ofv179. eCollection 2015 Dec. Open Forum Infect Dis. 2015. PMID: 26693494 Free PMC article.
The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
Sarpatwari A, Kesselheim AS. Sarpatwari A, et al. PLoS Med. 2016 Feb 9;13(2):e1001955. doi: 10.1371/journal.pmed.1001955. eCollection 2016 Feb. PLoS Med. 2016. PMID: 26859662 Free PMC article. Review.
82 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback